Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acetylcysteine
Drug ID BADD_D00032
Description Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of [acetaminophen] overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488]
Indications and Usage Acetylcysteine is indicated for mucolytic therapy and in the management of [acetaminophen] overdose.[L31378,L31383,L31388,L31478]
Marketing Status approved; investigational
ATC Code R05CB01; S01XA08; V03AB23
DrugBank ID DB06151
KEGG ID D00221
MeSH ID D000111
PubChem ID 12035
TTD Drug ID D06XGW
NDC Product Code 70594-111; 12598-7311; 49452-0098; 51552-0201; 51927-1601; 63323-694; 70710-1015; 55150-259; 66220-207; 0517-7610; 55154-5731; 12598-7302; 12598-7308; 12598-7323; 14445-412; 63323-963; 0409-3307; 0517-7504; 0517-7630; 72611-860; 83270-001; 25021-812; 63323-693; 63323-695; 0409-3308; 0517-7604; 17478-660; 63323-690; 63323-692; 0517-7510; 70771-1412; 52932-0704; 63323-691; 12598-7027; 52951-001; 0574-0805; 12598-7294; 12598-7327; 52133-0002; 52932-0742; 55154-5730
UNII WYQ7N0BPYC
Synonyms Acetylcysteine | N-Acetyl-L-cysteine | N Acetyl L cysteine | N-Acetylcysteine | N Acetylcysteine | Mercapturic Acid | Acid, Mercapturic | Solmucol | Genac | Acemuc | Acetabs | Acetylcystein AL | NAC AL | Acetylcystein Atid | Acetylcystein Heumann | Acetylcystein Trom | Acetylcysteine Hydrochloride | Hydrochloride, Acetylcysteine | Acetylcysteine Sodium | Sodium, Acetylcysteine | Acetylcysteine, Monosodium Salt | Monosodium Salt Acetylcysteine | Acetylcysteine Zinc | Zinc, Acetylcysteine | Acetylcysteine, (D)-Isomer | Acetylcysteine, (DL)-Isomer | Acetylcysteine, Monoammonium Salt | Monoammonium Salt Acetylcysteine | Acetyst | Acétylcystéine GNR | Airbron | Alveolex | Bromuc | Azubronchin | Bisolvon NAC | NAC, Bisolvon | Broncho-Fips | Broncho Fips | BronchoFips | Broncholysin | Broncoclar | Codotussyl | Cystamucil | Dampo Mucopect | Mucopect, Dampo | durabronchal | Larylin NAC | Eurespiran | Exomuc | Fluimucil | NAC Zambon | Zambon, NAC | Fabrol | Fluprowit | Optipect Hustengetränk | Hustengetränk, Optipect | Muco Sanigen | Sanigen, Muco | Frekatuss | Jenacystein | Jenapharm | Lantamed | Lindocetyl | M-Pectil | M Pectil | MPectil | mentopin Acetylcystein | Acetylcystein, mentopin | Muciteran | Mucomyst | Acetylin | Mucosil | Mucosol | Mucosolvin | Siccoral | Siran | Ilube | Hoestil | acebraus
Chemical Information
Molecular Formula C5H9NO3S
CAS Registry Number 616-91-1
SMILES CC(=O)NC(CS)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug abuse19.07.06.0100.000149%-
Drug hypersensitivity10.01.01.0010.001086%-
Drug ineffective08.06.01.0060.001518%-
Drug interaction08.06.03.0010.000149%-
Dyspepsia07.01.02.0010.000327%
Dysphagia07.01.06.0030.000149%
Dysphoria19.04.02.004---
Dyspnoea02.11.05.003; 22.02.01.0040.001369%
Ear disorder04.03.01.001---
Ear pain04.03.01.0030.000446%
Encephalopathy17.13.02.0010.000298%
Erythema23.03.06.0010.001175%-
Extravasation08.01.03.0080.000402%-
Eye pain06.08.03.002--
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Feeling hot08.01.09.009---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.0020.000149%
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.016--
Gastrointestinal disorder07.11.01.001---
Generalised oedema08.01.07.004; 14.05.06.0070.000223%
Generalised tonic-clonic seizure17.12.01.0020.000223%-
Haemolysis01.06.04.0020.000149%
Haemolytic anaemia01.06.03.0020.000223%-
Haemolytic uraemic syndrome01.06.02.001; 20.01.03.0110.000149%
Haemoptysis02.11.04.009; 22.02.03.004; 24.07.01.006---
Hepatic cirrhosis09.01.04.0010.000223%-
Hepatic encephalopathy09.01.03.006; 17.13.01.0030.000298%-
Hepatitis09.01.07.0040.000298%-
Hepatotoxicity09.01.07.009; 12.03.01.0080.000521%-
Hyperbilirubinaemia01.06.04.003; 09.01.01.003; 14.11.01.0100.000149%-
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene